Press release
Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan-- --Continuing to Advance
About this update from Insmed Incorporated
[{"type":"text","content":"--ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--\n --Continuing to Advance ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) Clinical Development Programs--\n --ARIKAYCE Total Revenue of $46.8 Million for the Third Quarter 2021--\n --Strong Cash Position of $846.6 Million as of September 30, 2021--\n\n\n\n BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. \n\"In the third quarter of 2021, Insmed made important progress against our strategic priorities, including steady performance of our commercial operations, advancement of our clinical development programs in line with expectations, and meaningful acceleration of our translational medicine efforts with a sharp focus on disruptive technologies that we believe will have a significant impact on patients' lives,\" commented Will Lewis, Chair and Chief Executive Officer of Insmed. \"Notably, we are excited about our launch progress for ARIKAYCE in Japan, where we are already seeing positive early trends. As we navigate this critical execution period for Insmed, we are well-capitalized and highly driven to launch the next phase of growth for our company and to serve many more patients around the world.\"\nRecent Corporate Developments & Program Highlights \nARIKAYCE \nInsmed launched ARIKAYCE in Japan in July of 2021, with a price in line with list prices in the U.S. and Europe. Initial uptake in Japan has been strong, with several positive trends at this early stage of the launch. Insmed continues to advance the launch of ARIKAYCE in Europe. In addition to previous launches in Germany and the Netherlands, ARIKAYCE has been reimbursed and launched in Wales as of September of 2021. The Company is pursuing country-by-country reimbursement throughout Europe, with a near-term focus on Ireland, additional UK countries, Italy, Belgium, and France. Enrollment continues in line with expectations in the post-approval confirmatory frontline clinical trial program of ARIKAYCE in patients nontuberculous mycobacterial (NTM) lung disease c...